ArticleScientific reports2025
Multi-biological activity evaluation of Sn(П), Zn(П) and Fe(П) complexes based on thiocarbohydrazide schiff bases: synthesis, spectroscopic investigations and fluorescence studies.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and In Vitro Evaluation of Atorvastatin and Rutin Co-Loaded Nanoliposomes for Enhanced Anti-Inflammatory and Cytotoxic Efficacy.International journal of molecular sciences · 2026Article
- Anticancer Activity of Schiff Base Metal Complexes Against MCF-7 Breast Cancer Cell Line.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two new Schiff base ligands (L1 and L2) were synthesized by condensing thiocarbohydrazide (TCH) with o-anisaldehyde or p-anisaldehyde in ethanol. Their mono- and bi-nuclear complexes with Sn(II), Zn(II), and Fe(II) were prepared for potential fluorescence and biological applications. Characterization was performed using FT-IR, NMR, UV-Vis spectroscopy, mass spectrometry, molar conductance, TGA, X-ray diffraction and SEM. XRD results indicated good crystallinity with crystallite sizes of 20-50 nm. Fluorescent intensity of free TCH ligands increased upon complexation with Sn, Zn, and Fe, suggesting their potential as fluorescence chemosensors. The compounds exhibited variable antimicrobial activities against Staphylococcus aureus, Escherichia coli, and Candida albicans, but lower than commercial drugs. L1Fe and L1Zn enhanced L1's cytotoxicity in four colorectal malignancy cells and L1Zn in skin cancer cells (A375), lung cancer cells (A549), uterine cervix cells (HeLa), and glioblastoma cells (U87). L1Fe showed enhanced activity in mammary adenocarcinoma cells (T47D) and triple-negative breast cancer cells (MDA-MB-231). L2Sn exhibited 70fold increase in L2's DPPH radical scavenging compared to the antioxidant ascorbic acid. L1Zn and L2Zn complexes outperformed indomethacin in reducing inflammation in RAW macrophages, enhancing the nanomolar efficacy of L1 and L2. These complexes have promising utility in cancer diagnosis, monitoring and highly selective duality of anti-inflammatory/cytotoxicity treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.